S. Snyder

Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma

G. Lyman, A. Nguyen, M. Gitlin, 2020, JAMA network open.

The Next Level in the Game of Playing for Formulary Preference

S Snyder, B Duffant, M Gitlin, 2018 .

Cost-Effectiveness and Estimated Health Benefits of Treating Patients with Vitamin D in Pre-Dialysis

C. Hollenbeak, K. Kalantar-Zadeh, M. Gitlin, 2020, Forum for health economics & policy.

Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care

Tina M. Albertson, M. Gitlin, S. Snyder, 2021, Advances in Therapy.

Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial.

A. Nguyen, T. Siddiqi, J. Abramson, 2021, Blood advances.

The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy

M. Bonafede, R. Maziarz, J. Tkacz, 2020, Leukemia & lymphoma.

The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3–4 CKD

C. Hollenbeak, K. Kalantar-Zadeh, A. Ashfaq, 2019, Journal of medical economics.